10 completed, 2 terminated. 9 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow serlopitant: new trials by email Literature Review of serlopitant trials Research Report on serlopitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa Serlopitant Tablet, Placebo Oral Tablet - Epidermolysis Bullosa | Phase 2 | Completed | Stanford University | 28 | 2019-04-18 | 2023-02-14 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin 5 mg Serlopitant Tablets, Matching Placebo Tablets - Pruritus | Phase 2 | Completed | Vyne Therapeutics Inc. | 233 | 2019-01-22 | 2021-05-20 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis 5mg Serlopitant Tablets, Placebo Tablets - Pruritus, Prurigo Nodularis | Phase 3 | Completed | Vyne Therapeutics Inc. | 295 | 2018-08-29 | 2021-05-20 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis 5mg Serlopitant Tablets, Placebo Tablets - Pruritus, Prurigo Nodularis | Phase 3 | Completed | Vyne Therapeutics Inc. | 285 | 2018-05-02 | 2021-05-20 |
| Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) 5 mg Serlopitant Tablets - Pruritus, Prurigo Nodularis | Phase 3 | Terminated | Vyne Therapeutics Inc. | 558 | 2018-03-15 | 2021-05-20 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis 5 mg Serlopitant Tablets, Matching Placebo Tablets - Pruritus, Psoriasis | Phase 2 | Completed | Vyne Therapeutics Inc. | 204 | 2017-11-01 | 2021-05-20 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough 5 mg Serlopitant Tablets, Matching Placebo Tablets - Refractory Chronic Cough | Phase 2 | Completed | Vyne Therapeutics Inc. | 185 | 2017-10-03 | 2021-05-20 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose - Pruritus, Atopic Dermatitis | Phase 2 | Completed | Vyne Therapeutics Inc. | 484 | 2016-11-01 | 2021-05-20 |
| Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury Serlopitant, Placebo - Pruritus, Burns | Phase 2 | Terminated | Vyne Therapeutics Inc. | 1 | 2016-11-01 | 2021-05-20 |
| Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients VPD-737, Placebo - Epidermolysis Bullosa, Pruritus | Phase 2 | Completed | Jean Yuh Tang | 14 | 2016-08-31 | 2020-03-23 |
| A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) serlopitant, Placebo - Prurigo Nodularis | Phase 2 | Completed | Vyne Therapeutics Inc. | 128 | 2014-07-09 | 2021-05-20 |
| VPD-737 for Treatment of Chronic Pruritus VPD-737, Placebo - Chronic Pruritus | Phase 2 | Completed | Vyne Therapeutics Inc. | 257 | 2013-10-15 | 2022-05-13 |
Pruritus (8) · Dermatitis, Atopic (3) · Epidermolysis Bullosa (2) · Psoriasis (2) · Burns (1) · Chronic Cough (1) · Lichenoid Eruptions (1)
Vyne Therapeutics Inc. (10) · Jean Yuh Tang (1) · Stanford University (1)
United States (10) · Germany (3) · Austria (2) · Poland (2) · United Kingdom (1)
Albert S Chiou, MD/MBA (1) · Edward F Schnipper, MD (1) · Franz Josef Legat, MD (1) · Jacek Szepietowski, MD, Ph.D (1) · Jacky Smith (1) · Jean Tang, MD, PhD (1) · Mary Spellman, MD (1) · Sonja Staender, MD (1) · Sonja Stander, MD (1)
PMID 31541747, PMID 29462657, PMID 32007513, PMID 32936233
2017 (3)